Rebamipid

Rebamipid
Nama sistematis (IUPAC)
	2-[(4-chlorobenzoyl)amino]-3-(2-oxo-1H-quinolin-4-yl)propanoic acid
Data klinis
Nama dagang	Mucosta (JP), Rebagen (KR, CN, IN), Rebagit (RU)
AHFS/Drugs.com	International Drug Names
Kat. kehamilan	?
Status hukum	?
Rute	Oral (tablets)
Pengenal
Nomor CAS	90098-04-7
Kode ATC	A02BX14
PubChem	CID 5042
Ligan IUPHAR	871
DrugBank	DB11656
ChemSpider	4866
UNII	LR583V32ZR
KEGG	D01121
ChEMBL	CHEMBL1697771
Data kimia
Rumus	C19H15ClN2O4
Massa mol.	370.786 g/mol
SMILES	eMolecules & PubChem
	InChI InChI=1S/C19H15ClN2O4/c20-13-7-5-11(6-8-13)18(24)22-16(19(25)26)9-12-10-17(23)21-15-4-2-1-3-14(12)15/h1-8,10,16H,9H2,(H,21,23)(H,22,24)(H,25,26) ; Key:ALLWOAVDORUJLA-UHFFFAOYSA-N ;

Rebamipide adalah turunan asam amino dari 2-(1H)-quinolinon yang digunakan untuk perlindungan mukosa, ^[1] penyembuhan tukak lambung (ulkus peptikum), dan pengobatan maag (gastritis).^[2] Obat bekerja dengan meningkatkan pertahanan mukosa, membersihkan radikal bebas,^[3] dan mengaktifkan gen penyandi siklooksigenase-2 secara sementara.^[4]

Rebamipide tersedia di sejumlah negara Asia termasuk Jepang (dipasarkan sebagai Mucosta), Korea Selatan, Cina,^[5] dan India (dipasarkan sebagai Rebagen), dan Rusia (dipasarkan sebagai Rebagit).^[6] Obat ini tidak disetujui oleh Badan Pengawasan Obat dan Makanan Amerika Serikat (US Food and Drug Administration).

Peneilitian telah menunjukkan bahwa rebamipide dapat melawan efek merusak NSAID pada mukosa GIT,^[7] dan baru-baru ini pada usus halus, tetapi tidak untuk kerusakan lambung yang diinduksi naproksen.^[8] Obat juga telah dipelajari untuk pengobatan penyakit Behçet.^[9] Itu terbukti berhasil mengobati pouchitis dalam studi N-tunggal setelah terapi lini pertama untuk kondisi tersebut tidak berhasil.^[10] Beberapa penelitian telah menunjukkan efektivitas pada presbyacusis (gangguan pendengaran terkait usia). ^[11]

Obat juga telah terbukti mengurangi tanda dan gejala mata kering (xerophtalmia) dalam uji coba terkontrol secara acak meskipun ini belum tersedia secara klinis.^[12]

Referensi

Templat:Drugs for peptic ulcer and GORD

^ Arakawa, T.; Kobayashi, K.; Yoshikawa, T.; Tarnawski, A. (1998). "Rebamipide: overview of its mechanisms of action and efficacy in mucosal protection and ulcer healing". Digestive Diseases and Sciences. 43 (9 Suppl): 5S–13S. ISSN 0163-2116. PMID 9753220.
^ Arakawa, T.; Watanabe, T.; Fukuda, T.; Yamasaki, K.; Kobayashi, K. (1995). "Rebamipide, novel prostaglandin-inducer accelerates healing and reduces relapse of acetic acid-induced rat gastric ulcer. Comparison with cimetidine". Digestive Diseases and Sciences. 40 (11): 2469–2472. ISSN 0163-2116. PMID 7587834.
^ Takumida, Masaya; Anniko, Matti (2009). "Radical scavengers for elderly patients with age-related hearing loss". Acta Oto-Laryngologica. 129 (1): 36–44. doi:10.1080/00016480802008215. ISSN 1651-2251. PMID 18607930.
^ Tarnawski, A. S.; Chai, J.; Pai, R.; Chiou, S. K. (2004). "Rebamipide activates genes encoding angiogenic growth factors and Cox2 and stimulates angiogenesis: a key to its ulcer healing action?". Digestive Diseases and Sciences. 49 (2): 202–209. ISSN 0163-2116. PMID 15104358.
^ drugs.com
^ "Russian State Register of Medicines. Registration Sertificate: Rebagit (rebamipide) Film-Coated Tablets" (dalam bahasa Russian). Diakses tanggal 10 June 2017.
^ Zhang, Shaoheng; Qing, Qing; Bai, Yang; Mao, Hua; Zhu, Wei; Chen, Qikui; Zhang, Yali; Chen, Ye (2013). "Rebamipide helps defend against nonsteroidal anti-inflammatory drugs induced gastroenteropathy: a systematic review and meta-analysis". Digestive Diseases and Sciences. 58 (7): 1991–2000. doi:10.1007/s10620-013-2606-0. ISSN 1573-2568. PMID 23456504.
^ Gagliano-Jucá, Thiago; Moreno, Ronilson A.; Zaminelli, Tiago; Napolitano, Mauro; Magalhães, Antônio Frederico N.; Carvalhaes, Aloísio; Trevisan, Miriam S.; Wallace, John L.; De Nucci, Gilberto (2016-06-04). "Rebamipide does not protect against naproxen-induced gastric damage: a randomized double-blind controlled trial". BMC gastroenterology. 16 (1): 58. doi:10.1186/s12876-016-0472-x. ISSN 1471-230X. PMC 4893238  . PMID 27259970. Pemeliharaan CS1: Format PMC (link)
^ "Efficacy of rebamipide as adjunctive therapy in the treatment of recurrent oral aphthous ulcers in patients with Behcet's disease: a randomised, double-blind, placebo-controlled study". Drugs in R&D. 4 (1): 19–28. 2003. doi:10.2165/00126839-200304010-00002. PMID 12568631.
^ http://www.wjgnet.com/1007-9327/12/656.pdf Error in webarchive template: Check |url= value. Empty.
^ Takumida, Masaya; Anniko, Matti (2005). "Radical scavengers: a remedy for presbyacusis. A pilot study". Acta Oto-Laryngologica. 125 (12): 1290–1295. doi:10.1080/00016480510037032. ISSN 0001-6489. PMID 16303676.
^ Kinoshita, S.; K. Oshiden; S. Awamura; H. Suzuki; N. Nakamichi (2013). "A randomized, multicenter phase 3 study comparing 2% rebamipide (OPC-12759) with 0.1% sodium hyaluronate in the treatment of dry eye". Ophthalmology. 120 (6): 1158–65. doi:10.1016/j.ophtha.2012.12.022. PMID 23490326.

[1] Arakawa, T.; Kobayashi, K.; Yoshikawa, T.; Tarnawski, A. (1998). "Rebamipide: overview of its mechanisms of action and efficacy in mucosal protection and ulcer healing". Digestive Diseases and Sciences. 43 (9 Suppl): 5S–13S. ISSN 0163-2116. PMID 9753220.

[2] Arakawa, T.; Watanabe, T.; Fukuda, T.; Yamasaki, K.; Kobayashi, K. (1995). "Rebamipide, novel prostaglandin-inducer accelerates healing and reduces relapse of acetic acid-induced rat gastric ulcer. Comparison with cimetidine". Digestive Diseases and Sciences. 40 (11): 2469–2472. ISSN 0163-2116. PMID 7587834.

[3] Takumida, Masaya; Anniko, Matti (2009). "Radical scavengers for elderly patients with age-related hearing loss". Acta Oto-Laryngologica. 129 (1): 36–44. doi:10.1080/00016480802008215. ISSN 1651-2251. PMID 18607930.

[4] Tarnawski, A. S.; Chai, J.; Pai, R.; Chiou, S. K. (2004). "Rebamipide activates genes encoding angiogenic growth factors and Cox2 and stimulates angiogenesis: a key to its ulcer healing action?". Digestive Diseases and Sciences. 49 (2): 202–209. ISSN 0163-2116. PMID 15104358.

[5] rugs.com

[6] "Russian State Register of Medicines. Registration Sertificate: Rebagit (rebamipide) Film-Coated Tablets" (dalam bahasa Russian). Diakses tanggal 10 June 2017.

[7] Zhang, Shaoheng; Qing, Qing; Bai, Yang; Mao, Hua; Zhu, Wei; Chen, Qikui; Zhang, Yali; Chen, Ye (2013). "Rebamipide helps defend against nonsteroidal anti-inflammatory drugs induced gastroenteropathy: a systematic review and meta-analysis". Digestive Diseases and Sciences. 58 (7): 1991–2000. doi:10.1007/s10620-013-2606-0. ISSN 1573-2568. PMID 23456504.

[8] Gagliano-Jucá, Thiago; Moreno, Ronilson A.; Zaminelli, Tiago; Napolitano, Mauro; Magalhães, Antônio Frederico N.; Carvalhaes, Aloísio; Trevisan, Miriam S.; Wallace, John L.; De Nucci, Gilberto (2016-06-04). "Rebamipide does not protect against naproxen-induced gastric damage: a randomized double-blind controlled trial". BMC gastroenterology. 16 (1): 58. doi:10.1186/s12876-016-0472-x. ISSN 1471-230X. PMC 4893238  . PMID 27259970. Pemeliharaan CS1: Format PMC (link)

[9] "Efficacy of rebamipide as adjunctive therapy in the treatment of recurrent oral aphthous ulcers in patients with Behcet's disease: a randomised, double-blind, placebo-controlled study". Drugs in R&D. 4 (1): 19–28. 2003. doi:10.2165/00126839-200304010-00002. PMID 12568631.

[10] ttp://www.wjgnet.com/1007-9327/12/656.pdf Error in webarchive template: Check |url= value. Empty.

[11] Takumida, Masaya; Anniko, Matti (2005). "Radical scavengers: a remedy for presbyacusis. A pilot study". Acta Oto-Laryngologica. 125 (12): 1290–1295. doi:10.1080/00016480510037032. ISSN 0001-6489. PMID 16303676.

[12] Kinoshita, S.; K. Oshiden; S. Awamura; H. Suzuki; N. Nakamichi (2013). "A randomized, multicenter phase 3 study comparing 2% rebamipide (OPC-12759) with 0.1% sodium hyaluronate in the treatment of dry eye". Ophthalmology. 120 (6): 1158–65. doi:10.1016/j.ophtha.2012.12.022. PMID 23490326.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

[11]

[12]